Roth Capital Predicts Lower Earnings for ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at Roth Capital cut their Q3 2027 earnings estimates for shares of ARS Pharmaceuticals in a note issued to investors on Monday, November 10th. Roth Capital analyst K. Bauser now forecasts that the company will post earnings of $0.32 per share for the quarter, down from their previous forecast of $0.41. Roth Capital has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

A number of other research firms also recently weighed in on SPRY. Wall Street Zen downgraded shares of ARS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. Zacks Research lowered shares of ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 22nd. Raymond James Financial set a $32.00 target price on shares of ARS Pharmaceuticals in a research report on Friday, September 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $31.80.

ARS Pharmaceuticals Stock Performance

ARS Pharmaceuticals stock opened at $8.41 on Wednesday. The company has a market cap of $831.33 million, a PE ratio of -10.38 and a beta of 0.83. The company has a current ratio of 6.66, a quick ratio of 5.98 and a debt-to-equity ratio of 1.14. ARS Pharmaceuticals has a 1 year low of $8.05 and a 1 year high of $18.90. The company’s 50-day moving average is $9.78 and its two-hundred day moving average is $13.43.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). The firm had revenue of $32.50 million for the quarter, compared to the consensus estimate of $28.87 million. ARS Pharmaceuticals had a negative return on equity of 38.77% and a negative net margin of 56.06%.

Insider Buying and Selling

In other news, CEO Richard E. Lowenthal sold 50,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $14.49, for a total value of $724,500.00. Following the sale, the chief executive officer directly owned 1,196,494 shares in the company, valued at $17,337,198.06. This trade represents a 4.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kathleen D. Scott sold 12,500 shares of the stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $15.00, for a total transaction of $187,500.00. Following the transaction, the chief financial officer owned 10,042 shares of the company’s stock, valued at $150,630. The trade was a 55.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 112,500 shares of company stock worth $1,615,759 over the last ninety days. Company insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC grew its holdings in shares of ARS Pharmaceuticals by 243.7% in the 3rd quarter. CWM LLC now owns 2,547 shares of the company’s stock valued at $26,000 after acquiring an additional 1,806 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of ARS Pharmaceuticals during the 1st quarter worth approximately $37,000. PNC Financial Services Group Inc. raised its stake in shares of ARS Pharmaceuticals by 78,100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock worth $49,000 after purchasing an additional 3,905 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of ARS Pharmaceuticals by 197.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after buying an additional 4,427 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at approximately $82,000. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.